119 related articles for article (PubMed ID: 10470198)
1. Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6)?
Wechsel HW; Feil G; Lahme S; Zumbragel A; Petri E; Bichler KH
Anticancer Res; 1999; 19(4A):2577-81. PubMed ID: 10470198
[TBL] [Abstract][Full Text] [Related]
2. [Significance of plasma interleukin-6 in the diagnosis of renal cell carcinoma].
Kamemoto H
Hinyokika Kiyo; 1993 Apr; 39(4):301-6. PubMed ID: 8503325
[TBL] [Abstract][Full Text] [Related]
3. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
4. TNF alpha, IL-1 beta and IL-6 production by peripheral blood monocytes in patients with renal cell carcinoma.
Ikemoto S; Sugimura K; Yoshida N; Wada S; Yamamoto K; Kishimoto T
Anticancer Res; 2000; 20(1A):317-21. PubMed ID: 10769674
[TBL] [Abstract][Full Text] [Related]
5. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
6. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
8. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma.
Ito K; Asano T; Yoshii H; Satoh A; Sumitomo M; Hayakawa M
Int J Urol; 2006 Nov; 13(11):1365-70. PubMed ID: 17083384
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.
Karakiewicz PI; Hutterer GC; Trinh QD; Jeldres C; Perrotte P; Gallina A; Tostain J; Patard JJ
Cancer; 2007 Sep; 110(6):1241-7. PubMed ID: 17639589
[TBL] [Abstract][Full Text] [Related]
10. The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer.
Ramsey S; Lamb GW; Aitchison M; McMillan DC
Br J Cancer; 2006 Oct; 95(8):1076-80. PubMed ID: 17003778
[TBL] [Abstract][Full Text] [Related]
11. Serum gamma glutamyl-transferase is a sensitive but unspecific marker of metastatic renal cell carcinoma.
Simic T; Dragicevic D; Savic-Radojevic A; Cimbaljevic S; Tulic C; Mimic-Oka J
Int J Urol; 2007 Apr; 14(4):289-93. PubMed ID: 17470155
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
Negrier S; Perol D; Menetrier-Caux C; Escudier B; Pallardy M; Ravaud A; Douillard JY; Chevreau C; Lasset C; Blay JY;
J Clin Oncol; 2004 Jun; 22(12):2371-8. PubMed ID: 15197198
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade.
Sözen S; Coskun U; Sancak B; Bukan N; Günel N; Tunc L; Bozkirli I
Neoplasma; 2004; 51(1):25-9. PubMed ID: 15004655
[TBL] [Abstract][Full Text] [Related]
14. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage.
Singh KJ; Singh SK; Suri A; Vijjan V; Goswami AK; Khullar M
Indian J Cancer; 2005; 42(4):197-200. PubMed ID: 16391438
[TBL] [Abstract][Full Text] [Related]
15. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive acidic protein detects high nuclear grade localized renal cell carcinoma.
Kawata N; Yamaguchi K; Hirakata H; Hachiya T; Yoshida T; Takimoto Y
Urology; 2005 Oct; 66(4):736-40. PubMed ID: 16230127
[TBL] [Abstract][Full Text] [Related]
17. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K
Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma.
Wittke F; Hoffmann R; Buer J; Dallmann I; Oevermann K; Sel S; Wandert T; Ganser A; Atzpodien J
Br J Cancer; 1999 Mar; 79(7-8):1182-4. PubMed ID: 10098756
[TBL] [Abstract][Full Text] [Related]
19. Serum amyloid A: a biomarker for renal cancer.
Fischer K; Theil G; Hoda R; Fornara P
Anticancer Res; 2012 May; 32(5):1801-4. PubMed ID: 22593464
[TBL] [Abstract][Full Text] [Related]
20. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
